286 related articles for article (PubMed ID: 37058763)
1. SARS-CoV-2 pandemic as a model to assess the relationship between intercurrent viral infections and disease activity in Multiple Sclerosis: A propensity score matched case-control study.
Vercellino M; Bosa C; Alteno A; Muccio F; Marasciulo S; Garelli P; Cavalla P
Mult Scler Relat Disord; 2023 Jun; 74():104715. PubMed ID: 37058763
[TBL] [Abstract][Full Text] [Related]
2. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M;
Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084
[TBL] [Abstract][Full Text] [Related]
3. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 triggered relapse of multiple sclerosis.
Finsterer J
Clin Neurol Neurosurg; 2022 Apr; 215():107210. PubMed ID: 35305393
[TBL] [Abstract][Full Text] [Related]
5. Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic?
Tazza F; Lapucci C; Cellerino M; Boffa G; Novi G; Poire I; Mancuso E; Bruschi N; Sbragia E; Laroni A; Capello E; Inglese M
J Neurol Sci; 2021 Aug; 427():117501. PubMed ID: 34044238
[TBL] [Abstract][Full Text] [Related]
6. A one year follow of patients with multiple sclerosis during COVID-19 pandemic: A cross-sectional study in Qom province, Iran.
Paybast S; Hejazi SA; Molavi P; Habibi MA; Naser Moghadasi A
Mult Scler Relat Disord; 2022 Apr; 60():103712. PubMed ID: 35247752
[TBL] [Abstract][Full Text] [Related]
7. Comparing humoral immune response to SARS-CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study.
Bsteh G; Hegen H; Traxler G; Krajnc N; Leutmezer F; Di Pauli F; Kornek B; Rommer P; Zulehner G; Dürauer S; Bauer A; Kratzwald S; Klotz S; Winklehner M; Deisenhammer F; Guger M; Höftberger R; Berger T
Eur J Neurol; 2022 May; 29(5):1538-1544. PubMed ID: 35102646
[TBL] [Abstract][Full Text] [Related]
8. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
[TBL] [Abstract][Full Text] [Related]
9. Relapses after SARS-CoV-2 vaccination in patients with neuromyelitis optica spectrum disorder and multiple sclerosis.
Kong L; Wang X; Chen H; Shi Z; Lang Y; Zhang Y; Zhou H
Mult Scler Relat Disord; 2022 Dec; 68():104167. PubMed ID: 36170773
[TBL] [Abstract][Full Text] [Related]
10. Effect of the COVID-19 pandemic on disease activity in multiple sclerosis patients treated with hematopoietic stem cell transplantation.
Mariottini A; Lotti A; Innocenti C; Repice AM; Nozzoli C; Boncompagni R; Fainardi E; Saccardi R; Massacesi L
Eur J Neurol; 2023 Oct; 30(10):3362-3366. PubMed ID: 37483174
[TBL] [Abstract][Full Text] [Related]
11. Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries.
Hrnciarova T; Drahota J; Spelman T; Hillert J; Lycke J; Kubala Havrdova E; Recmanova E; Adamkova J; Mares J; Libertinova J; Pavelek Z; Hradilek P; Ampapa R; Stetkarova I; Peterka M; Martinkova A; Stourac P; Grunermelova M; Vachova M; Dufek M; Horakova D
Mult Scler Relat Disord; 2023 Aug; 76():104803. PubMed ID: 37329786
[TBL] [Abstract][Full Text] [Related]
12. Antibodies against SARS-CoV-2 S and N proteins in relapsing-remitting multiple sclerosis patients treated with disease-modifying therapies.
Kulikowska J; Czarnowska A; Gudowska-Sawczuk M; Kulczyńska-Przybik A; Bazylewicz M; Collins F; Chorąży M; Mroczko B; Kochanowicz J; Kapica-Topczewska K; Kułakowska A
Neurol Neurochir Pol; 2023; 57(1):121-130. PubMed ID: 36421067
[TBL] [Abstract][Full Text] [Related]
13. The disease course of multiple sclerosis before and during COVID-19 pandemic: A retrospective five-year study.
Babtain F; Bajafar A; Nazmi O; Badawi M; Basndwah A; Bushnag A; Cupler E; Hassan A
Mult Scler Relat Disord; 2022 Sep; 65():103985. PubMed ID: 35759904
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis.
Smith JB; Gonzales EG; Li BH; Langer-Gould A
JAMA Netw Open; 2022 Dec; 5(12):e2248664. PubMed ID: 36576740
[TBL] [Abstract][Full Text] [Related]
15. Predictors for insufficient SARS-CoV-2 vaccination response upon treatment in multiple sclerosis.
Schraad M; Uphaus T; Runkel S; Hitzler W; Bittner S; Zipp F
EBioMedicine; 2023 Jan; 87():104411. PubMed ID: 36535106
[TBL] [Abstract][Full Text] [Related]
16. Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies.
Smith TE; Madhavan M; Gratch D; Patel A; Saha V; Sammarco C; Rimler Z; Zuniga G; Gragui D; Charvet L; Cutter G; Krupp L; Kister I; Ryerson LZ
Mult Scler Relat Disord; 2022 Apr; 60():103735. PubMed ID: 35398713
[TBL] [Abstract][Full Text] [Related]
17. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
18. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 infection and seroprevalence in patients with multiple sclerosis.
Piñar Morales R; Ramírez Rivas MA; Barrero Hernández FJ
Neurologia (Engl Ed); 2021; 36(9):698-703. PubMed ID: 34103271
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19.
Corchado-Garcia J; Zemmour D; Hughes T; Bandi H; Cristea-Platon T; Lenehan P; Pawlowski C; Bade S; O'Horo JC; Gores GJ; Williams AW; Badley AD; Halamka J; Virk A; Swift MD; Wagner T; Soundararajan V
JAMA Netw Open; 2021 Nov; 4(11):e2132540. PubMed ID: 34726743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]